Review Article
Contemporary Clinical Management of Endometrial Cancer
Table 10
GOG trials of hormone therapy in endometrial cancer.
| | GOG study and dosing | RR (%) | PFS (months) | OS (months) | DOR (months) |
| | 153 MA 80 mg BID × 3 weeks alternating with T 20 mg BID × 3 weeks | | 2.7 months | 14.0 months | 28 months | | 121 high dose MA 800 mg daily | | 2.5 months | 7.6 months | 8.9 months | | 81 MA high dose 1000 mg daily versus low dose 200 mg daily | high dose
low dose | 2.5 months
3.2 months | 7.0 months
11.1 months | NR | | 119 T 200 mg BID + MPA 100 mg BID intermittently weekly | | 3.0 months | 12.8 months | NR | | 81F T 20 mg BID | | 1.9 months | 8.8 months | NR |
|
|
MA: megastrol acetate; T: tamoxifen; MPA: medroxyprogesterone acetate; RR: response rate; PFS: progression free-survival (median); OS: overall survival (median); DOR: duration of response (median); NR: not reported.
|
